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Abstract.  Integrin Associated Protein (LAP) is a 50- 
kD membrane protein which copurifies with the inte- 
grin a4~3 from placenta and coimmunoprecipitates 
with 153 from platelets.  IAP also is functionally as- 
sociated with signal transduction from the Leukocyte 
Response Integrin.  Using tryptic peptide sequence, hu- 
man and murine IAP cDNAs have been isolated. The 
protein has an extracellular amino-terminal  immuno- 
globulin domain that binds all monoclonal anti-LAP 
antibodies.  The carboxy-terminal region is highly hy- 
drophobic with three or five membrane-spanning  seg- 
ments and a  short hydrophilic tail.  Immunofluores- 
cence microscopy suggests that this hydrophilic tail is 
located on the inside of the cytoplasmic membrane. 
Monoclonal anti-IAP antibody inhibits the binding 
of vitronectin-coated beads to c~vfl3 on human erythro- 
leukemia cells, and polyclonal anti-IAP recognizes 
hamster LAP on CHO cells and inhibits vitronectin 
bead binding.  When CHO cells are transfected with 
human LAP, monoclonal anti-human  antibody com- 
pletely inhibits vitronectin bead binding.  These 
data suggest a model in which ligand binding by otv~3 
is regulated by IAE 
HESION receptors  of the  integrin  family  recognize 
several  proteins  of  the  extracellular  matrix  and 
appear to be critical for the induction of normal mor- 
phology and migration  of many cell types (2, 4, 6, 22, 31). 
While the interaction of integrins with their ligands has been 
the subject of intense study over the past several years, much 
less  information  has  been  gathered  about  the  molecular 
mechanisms  by which integrins  affect cell phenotype and 
function.  Recently, we described a cell surface protein which 
we  copurified  with  the  integrin  avfl3 from  placenta  and 
which also coimmunoprecipitated  with  f13 integrins  from 
platelets  (5). This coprecipitating  protein had a Mr of ~50 
kD on SDS-PAGE, was highly hydrophobic,  and was widely 
expressed. The 50-kD protein itself did not recognize the 
Arg-Gly-Asp peptides with which ot453 was purified (5), but 
mAb recognizing  the 50-kD protein could inhibit  several 
neutrophil  and monocyte functions mediated by a leukocyte 
fl3-1ike integrin,  including  ligand  binding  (5,  16,  17,  35). 
Therefore,  we hypothesized  that the 50-kD protein,  which 
we called Integrin-associated  Protein (IAP), ~ could physi- 
cally associate with  some integrins  and,  without directly 
binding  the integrin  ligands,  could regulate  integrin  func- 
tion. Now, we have cloned IAP eDNA from both human and 
mouse cells and examined its structure and role in binding 
vitronectin  (Vn) ligand  in native and transfected  cells. 
Materials and Methods 
Tissue Culture 
Tissue  culture cells were grown at 37°C,  5% CO2,  in Iscove's Modified 
Dulbecco's Medium (GIBCO BRL, Gaithersburg, MD), supplemented with 
10% FCS (Hyclone Labs., Logan, UT). For bead binding, CHO cells were 
grown in Ham's F12 with 10% FCS supplemented with 250 #g/ml active 
G418. 
Antibodies 
The mouse IgG1 anti-IAP mAbs used have been described previously  (5, 
16). B6H12, 1F7, 2B7, 2Ell, and 3E9 are inhibitory to Leucocyte Response 
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phils. 2D3 and 3G3 are non-inhibitory. All antibodies immunoprecipitate 
IAP. mAh 6F2 is an isotype matched control. 
Preparation of  Anti-Peptide Antibodies 
A peptide, CNQKTIQPPRNN, was synthesized  by the Washington Univer- 
sity Protein Chemistry facility.  This peptide corresponds to the carboxy- 
terminal II amino acids  predicted  by ptAP3, with an amino-terminal cys- 
teine  added for conjugation to keyhole limpet hemocyanin. Cross-linking 
was performed using the  bifunctional  cross-linker  bromacetylsuccinimidc, 
as previously  described (16).  Rabbits were immunized with 50 fig  of  the 
protcin-peptide  conjugate  in  complete  Freund's  adjuvant,  and  then  20  d later 
in  incomplete Freund's  adjuvant.  Immunization in  incomplete Freund's  was 
continued on a monthly basis for 2 mo. 
mAbs against the human tAP carboxy terminus were prepared as de- 
scribed (16) using 50 ~tg of the peptide conjugate per injection. The two 
mAbs used in this study both immunoprecipitate human tAP and hind to 
the human carboxy-terminal peptide. Miapl51 also reacts with the corre- 
sponding peptide derived from the mouse sequence, whereas miapl31 does 
not, demonstrating that the two mAbs have different antigen combining 
sites. 
IAP Cloning 
Standard techniques were used for cloning and other nucleic acid manipula- 
tion (32). A tryptic peptide sequence, VEFTFCNDTVVIPCFVTNMEAQ, 
was obtained from tAP purified from placenta, as previously described (5). 
Based on this sequence, two degenerate oligonucleotides were synthesized 
and used for PCR using a U937 CDNA library in ~,tl0 (the kind gift of 
Dr. Douglas Lublin, Washington University) as template. The forward oli- 
gonucleotide was 5'-GTIGA(ag)TT(te)ACITT(te)TG(te)AA(te)GA-3', and 
the  inverse  was  5'-TGIGC(TC)TCCAT(ng)TTIGTIAC(ng)AA(ag)CA-3'. 
The PCR product of 66 bp was cloned into pBinescriptlI-KS(+) (Stra- 
tagene,  La  Jolla,  CA),  sequenced (33)  to  confirm that it  encoded the 
expected peptide, and used to probe the U937 cDNA library using conven- 
tional techniques. The EcoRI insert was subcloned from the phage into 
pBhiescriptII-KS(+) resulting in pIAP0. A 5'-fragment (EcoRI-Xmnl) of 
the ptAP0 insert was used to screen a )~ZAPII (Stratagene) cDNA library 
from differentiated HL60 cells (the kind gift of Dr. Brian Volpp, University 
of Iowa), from which several clones containing the entire coding sequence 
were obtained. Two clones, ptAP3 and ptAP4, were sequenced to obtain 
unambiguous overlapping readings from both strands. Plasmid ptAP4 con- 
tains tAP with the longest 5' untranslated sequence, but the plasmid also 
contains a second unrelated cDNA. Therefore, ptAP3 was used for all fur- 
ther studies. Several other clones were sequenced on one strand or partially. 
These clones varied in the length of their 5' and 3' untranslated sequences, 
but were identical to ptAP3 in the coding region to the extent of the se- 
quence obtained. The sequence submitted to Genhank (Fig.  1; Accession 
number 7_25521) is the synthesis of the sequences obtained from pIAP3 
and ptAP4.  Pinsmid pIAP0 has a  32 bp deletion (Fig.  1) compared to 
ptAP3/ptAP4 at the 3' end of  the coding sequence, presumably due to alter- 
native splicing. 
Murine tAP cDNA was obtained by screening a cDNA library from the 
70Z/3 pre-B cell line using the full length human tAP cDNA under condi- 
tions of intermediate stringency. One of  the initial clones, ptAP28, was used 
for further study.  The library was rescreened with a 5' murine IAP probe 
to obtain clones with as much 5' untranslated sequence as possible. The 5' 
end of the clone with the longest 5' untranslated sequence, pIAP42, was se- 
quenced. The 5' untranslated region of ptAP28 was identical to the corre- 
sponding region of  ptAP42. The sequence submitted to Genbank (accession 
number Z25524) is the synthesis  of  the sequence obtained from ptAP28 and 
pIAP42. 
Sequence Analysis 
The National Center of Biotechnology Information (NCBI) electronic mail 
servers BLAST (25) and RETRIEVE were used to find and retrieve homol- 
ogous sequences. Sequence comparison was done by the Needleman and 
Wunsch algorithm (10) with the protein alignment matrix PAM250,  a bias 
of 10, and a gap penalty of 10. The result for a pair of sequences was given 
as standard deviations of the score above the mean of the alignment score 
for 150 random permutations of the same sequences. Hydrophobicity plots 
were calculated as described by Kyte and Doolittle (39) using a window of 
11  residues. 
Construction of  lAP Expression Plasmids and 
Chimeric IAP Genes 
ptAP3 was digested with HindlII and Xbal, which cut in the pBluescriptII- 
SK(-) polylinker just 5' and 3' of the insert, respectively. The resulting 
HindIII-XbaI  fragment was ligated into pRC/RSV (Invitrogen, La Jolla, 
CA) digested with the same enzymes, yielding ptAP45, tAP was divided 
into three regions, delimited by stretches of amino acid sequence identity 
between the human and mouse variants. The delimiting sequences were 
chosen so that unique restriction sites could be introduced into the cDNAs, 
without altering the amino acid sequence. Using PCR, the gene segments 
were obtained individually, subcloned, and sequenced. Fig.  1 shows the 
doubly underlined regions of homology between the oligonucleotides used 
and the human IAP cDNA sequence. The letters labeling the regions are 
placed under the amino acids delimiting the segments. The corresponding 
point in the mouse sequence can be deduced from the alignment in Fig. 2. 
The 5' hydrophobic segment encoding region (amino acids MI-S Is) was 
obtained as an )~aI-BamHI fragment (oligonucleotides  5'-GAAG TC~ 
CC ATG TGG CCC CTG GTA GCG-3' and 5'-TAG CTG AGC GGATCC 
GCA GCA GC-3' for human tAP, and 5'-GAAG TCTAGA CC ATG TGG 
CCC TTG GCG GCG-3'  and 5'oTAG TTG  AGC GC~TCC  GCA GCA 
GC-3'  for mouse tAP;  Fig  1.  segment a-b).  The  DNA  encoding the 
hydrophilic domain (S18-wl36)  was obtained as a BamHI-PvulI fragment 
(5'-C'IUK2 GC~TCC GCT CAG CTA CTA-3' and 5'-GAAA CTG ~TG 
ACA ACA CGA TAT TTT AG-3' for human IAP, and 5'-CTGC GGATCC 
GCT CAA CTA CTG-3'  and 5'-GAAA C~GCTG  ACT AAT TTG 
CAA CCT CC-3' for murine tAP; Fig 1. segment b-c). The remainin~ part 
of the cDNA  (W131-N3°5),was  made as a  PvuH-HindlII  fragment (5'- 
GTTG ~TGG  TTT TCT CCA AAT GAA-3' and 5'CCC 
AGA TCT TTC ACG TCT TAC TAC TC-3' for human tAP, and 5'-GTTG 
CTGCAGCTGG  TTT  TCT CCA AAT GAA-3' and 5'-CCC  AAGCTT 
AGAT CTC TGT ATT CTT CCA TTT CTG-3' for mouse tAP; Fig 1. seg- 
ment c-d). The three different fragments were assembled and put under the 
control of the T7 promoter in pBC-KS(-) (Stratagene, La Jolla, CA). The 
clones were designated pIAP57 (all human), plAF79 (all murine), plAP67 
(human with murine hydrophilic region b-c), and pIAF76 (murine with hu- 
man hydrophilic region b-c). 
FOr transfection, the inserts from the various chimeric clones were ob- 
tained as HindlII-XbaI  fragments and cloned into the expression vector 
pIAP58 (unpublished; pRC/RSV with a replaced polylinker reversing the 
order of the HindIII and XbaI sites), yielding plasmids p AP70, pIAP83, 
pIAP72,  and  ptAPS0,  respectively.  An  anti-sense  control  construct, 
pIAP69, was constructed by cloning the all human insert into pRC/RSV. 
FACScan and FACSorting 
Fluorescent flow microcytometry was performed using anti-human tAP 
mAbs precisely as described (5). Before incubation with anti-IAP mAbs, 
CHO cells were removed from tissue culture plates by incubation with 
trypsin-EDTA and washed twice with PBS. For FACSortlng, cells were re- 
moved from the plates using Dulbecco's PBS with 2 mM EDTA, stained, 
resuspended to 5  ×  106 cells/ml, and sorted in an Epics 753 FACSorter. 
Generally, the 5 % most fluorescent cells were recovered. 
Transfection of CHO Cells 
CHO cells were grown to 50% confluence in 35-ram diam dishes and trans- 
fected with 3/tg plasmid DNA using the calcium phosphate method (15). 
Cells were grown for 24 h in nonselective  medium. They were then removed 
with trypsin-EDTA and seeded into 25 cm  2 flasks containing medium with 
600 t~g/ml active CJ418 (GIBCO BRL). After 14 d, the pool of survivors 
was analyzed by FACScan. For subsequent experiments, enrichment for ex- 
pressors was carried outby FACSorting the 5% highest staining cells using 
an anti-IAP mAb (1F7) as primary antibody. Anti-sense and vector control 
transfectants were sorted similarly. 
Immunoprecipitation 
For immunoprecipitation, U937 cells, CHO cells, or platelets were labeled 
with biotin hydrazide. Cells were washed with biotinylation buffer (0.15 M 
NaC1, 0.05 M acetate, pH 5.5), incubated with 10 mM NaIO4 in the same 
buffer for 30  rain on ice,  and  washed with biotinyintion buffer.  Biotin 
hydrazide (2/tg/ml) was added and incubation continued for 1.5 h at 4°C. 
The cell pellet was subsequently washed twice with PBS and lysnd in PBS 
containing l%Triton X-100, 1% deoxycholate, and 2 mM PMSE After cen- 
trifugation for 15 rain at 15,000 g to remove cell debris, the lysate was used 
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tein A-Sepharose (Pharmacia LKB Biotechnology,  Piscataway, NJ) or 100 
#1 of monoclonal antibody tissue culture supernatant was incubated with 20 
#1 anti-mouse IgG-Sepharose (Cappel  Organon-Technica,  West Chester, 
PA). The antibody-charged Sepharose was washed and added to 200 #1 of 
cell lysate,  incubated for 2 h to overnight at 4°C, washed twice with lysis 
buffer, and twice with PBS containing 0.05 % Tween-20. The Sepharose pel- 
let was heated to 65°C for l0 rain in Laemmli buffer for SDS-PAGE (9), 
the sample electrophoresed through a 10% SDS-PAGE gel and transferred 
to polyvinylidine difluoride  paper (Milipore,  Bedford, MA). Immunopre- 
cipitated proteins were detected using streptavidin conjugated to horserad- 
ish peroxidase (Jansen Biochimica, Belgium) and chemiluminescence per- 
oxidase  substrate (ECL, Amersham Corp., Arlington Heights,  IL). 
In Vitro Translation 
Wild-type  and mutant lAP cDNAs were cloned into pBluescriptlI-KS(+) 
under the control of the phage T7-promoter.  The plasmids were linearized 
at the 3'-end of lAP and in vitro transcribed by TT-RNA polymerase in the 
presence of 500 #M mTG(53ppp(53G cap analogue (New England Biolabs, 
Beverly, MA). The RNA was in vitro translated using rabbit reticulocyte 
lysate in the presence of [3SS]methionine (Amersham Corp.), and canine 
pancreatic microsomal membranes for cotranslational  processing (Promega 
Corp., Madison, WI), according to the manufacturer's instructions. In vitro 
translated products were immunoprecipitated with various anti-lAP mAb 
or an isotype matched irrelevant control, as described above. Supernatants 
of negative immunoprecipitations were analyzed by SDS-PAGE to confirm 
the presence of an appropriate size in vitro translation product. 
Preparation of Vitronectin-coated Beads 
Ligand-coated  beads  were  prepared  by  incubating  4  ×  10  s  1.3  /zm 
aldehyde-modified fluorescent latex beads (Molecular Probes, Eugene, OR) 
with 10/zg purified Vn (Telios Pharmaceuticals, San Diego, CA), fibronec- 
tin (Fn, Telios), or human serum albumin (HSA) as a control in 200 ~1 of 
PBS. After 1 h at 37°C,  10 mg of HSA in 800 ~1 PBS was added to quench 
unreacted sites. After 1 h the beads were washed and resuspended in 1 nd 
of HBSS containing divalent cations (see below) and 1% HSA. Immediately 
before use, the preparations were soaicated for 1-2 s to disrupt aggregates. 
Vitronectin-bead Binding 
Vn-bead and Fn-bead binding to human erythroleukemia (HEL) cells was 
assessed by a modification of the previously described assay (17). The stan- 
dard incubation mixture contained 1.5  x  10  ~ cells, various concentrations 
of antibodies, and 45 #1 of ligand-coated  beads in a volume of 130 #1. The 
incubation buffer for Vn-beads was HBSS with 1% HSA, 2 mM CaC12, 1 
mM MgCI2, and 1 mM MnCI2. The incubation buffer for Fn-beads was 
identical  except for omission of the CaCI2 and MgC12. These divalent cat- 
ion conditions allowed maximal binding of Vn-beads to uJ~3 and Fn-beads 
to ~5/31 without interaction with other cell surface receptors. For antibody 
inhibition studies,  ceils were incubated with various monoclonal and poly- 
clonal antibodies for 15 rain at room temperature and for 15 rain before the 
addition of the beads.  The antibodies used were rabbit nonimmune IgG (18 
#g); rabbit anti-VnR (16) 1:100; rabbit  IgG anti-lAP (18 t~g); rabbit anti-FnR 
(Telios) 1:100; murine IgG1 anti-lAP mAb 2D3 (22 t~g); murine IgG/anti- 
lAP mAb B6H12 (22/zg); murine IgG1 anti-153  mAb 7G2 (25 #g); and mu- 
rine anti-as IgG3 mAb P1D6 (Telios,  1:100). After 1 h at 37°C,  the cells 
were washed three times in PBS and the number of beads bound assessed 
by microscopy.  Binding was quantitated as an attachment index (AI), the 
number of beads bound per 100 cells. 
Binding experiments with CHO transfectants were performed essentially 
identically, except that 2  x  104 CHO cells were adhered to glass 4-chamber 
LabTek slides (Nunc Inc., Naperville, IL) overnight and used as adherent 
cells. The total volume of the reaction mixture in the LabTek chamber was 
500 ~1, and antibody additions were increased to keep the concentration 
similar to that used for the HEL ceils in suspension. 
Results 
Cloning of  lAP 
To determine the structure of IAP, we cloned its cDNA from 
a U937 3~rtl0 cDNA library (27). Several cDNAs were ana- 
-138  GCGTGCGCGC~CCGTGCAGCCTG~GTC'C'GTCC~CCTGTGACGCGC~C~C~TC  -79 
-78  GGTCCTGCC~T~C~C~C~C~CTG~GCTC~GACACCTGC~C~CGGC~CGA  -19 
MWPLVAALLLGSAC  14 
-18  CCCCGCGGCC-GGCGC~AGA~T~CCCCTGGTAGC~CGCTGTTGCT~GCTCGGCGTG  41 
=(a)  ........  =ffi====  ...... 
15CGSAQLLFNKTKSVEFTFCN  34 
42  CTGCG~TCAGCTCAGCTACTA~T~T~CA~JiATCTGTAG~TTCACGTT~GT~  101 
......  (b)==  ........... 
35DTVVIPCFVTNMEAQNTTEV  54 
102  TGA~CI'GTCGT~TTC~TGCT~GTTACT~TATGGA~CACAAAA~CTACTG~GT  161 
55YVKWKFKGRDIYTFDGALNK  74 
162  ATACGTAAAGT~AAA~TAAAGG~GAGATA~TA~CCTTTGATGGAGCTCTAAAC~  221 
75STVPTDFSSAKIEVSQLLKG  94 
222  GTCCAC~TCCCCACTGACTTTAGTAGTGC/~TTG~GTCTCAC~TTACT~GG  281 
95DASLKMDKSDAVSHTGNYTC  114 
282  AGAT~CTCT~ITG~GATGGAT~GAGTGATGCTGTCTCACACA~GGA~CTA~CT~  341 
115  E  V  T  E  L  T  R  E  G  E  T  I  I  E  L  K  Y  R  V  V  134 
342  TGAAGT~CAG~-~TTAAC  CAGAGAAGGTC~CGAT  CAT  CGAG  CTA~TAT  CGTGTT  GT  401 
135  S  W  F  S  P  N  E  N  I  L  I  V  I  F  P  I  F  A  I  L  154 
402  TTCATGGTTTT CT  CCAAATGAAAATATTC TTATTGTTATTT TC  C  CAATTTTTGC TATAC  T  461 
===  (c)  =  ............... 
155  L  F  W  G  Q  F  G  I  K  T  L  K  Y  R  S  G  G  M  D  E  174 
462  C  CTGTT  CTC~3GGACAGTTTGGTATT~CACTTI~TATAGAT  CC  GGTC~  TATGGATGA  521 
175  K  T  I  A  L  L  V  A  G  L  V  I  T  V  I  V  I  V  G  A  194 
522  G~CAATTGC"I~TACTTGTTG  CTGGACTAGTGATCAC TGT  CATTGTCATTGT TGGAGC  581 
195  I  L  F  V  P  G  E  Y  S  L  K  N  A  T  G  L  G  L  I  V  214 
582  CATT  CTTTTCGTCC CAGGTGAATATT CATTA~GAATGC  TAC  TGGCC  TTGGT  TTAATTGT  641 
215  T  S  T  G  I  L  I  L  L  H  Y  Y  v  F  S  T  A  I  G  L  234 
642  GACTTCTACAC-C~TAT  TAATATTACTT CACTACTATG  TGTTTAG  TACAG  CGATT  GGATT  701 
235  T  S  F  V  I  A  I  L  V  I  Q  v  I  A  Y  I  L  A  V  V  254 
702  AACCT  C  CTTC  GT  CAT  TGCCATATTGGTTATT CAGGT  GATAG  CC  TATAT  C  CT  CG  CTGTGGT  761 
255  G  L  S  L  C  I  A  A  C  I  P  M  H  G  P  L  L  I  S  G  274 
762  ~GACTGAGT  CTC  TGTAT  TGCGGCGTGTATAC CAATG  CATGGC  C  CT  CTT  CT  GATTT  CAGG  821 
275  L  S  I  L  A  L  A  Q  L  L  G  L  V  Y  M  K  F  V  A  S  294 
822  TTTGAG  TAT  CTTAGCT  CTAGCACAATTACTTGGACTAGTTTATATGI~TTTGT  GG  CTTC  881 
295  N  Q  K  T  I  Q  P  P  R  N  N  305 
882  CAAT  CAGAAGACTATACAACC T  C  CTAGGAATAACTGAAGT GAAGTGATGGAC T  C  CGATTT  941 
............................ 
942  C-GAGAGTAGTAAGACGT  GAAAGGAATACACTTGTGTTTAAGCACCATGGC  CTTGATGATT  i001 
.......  ~ ....  =  .......  (d)  = 
1002  CACTG  TTGC~AGAAC~CAAGA~GT~CTGGTTGTCACC  TATGAGAC  CC  TTACGTG  1061 
1062  ATTGTTAGTTAAGTTTTTATT  CAAAGCAGCTGTAATTTAGTTAAT~TAATTATGAT  C  ii~i 
1122  TA~ 
Figure 1.  Sequence of human IAP cDNA.  Nucleotides are num- 
bered relative to the start of the initiation cedon. The cDNA ends 
with a short poly-A tail, preceded by a poly-adenylation site. Above 
the  sequence  the  deduced  amino  acid  sequence  (in  one-letter 
IUPAC  code)  is  shown,  starting  with  the  initiator methionine. 
Regions homologous to the oligonucleotides used for construction 
of IAP chimeras (see Materials and Methods) are doubly under- 
lined. In each case, the letter naming the region indicates the point 
of fusion between the PCR fragments. The singly underlined se- 
quence  is  the  region  absent  from  the  U937  clone and  a  small 
minority of the HL60 clones. This would lead to a protein terminat- 
ing in K2~FVE. 
lyzed which all ended at a 5' EcoRI site within the open read- 
ing frame. PCR analysis of the cDNA library failed to reveal 
full  length  clones,  presumably  due  to  incomplete  EcoRI 
methylation of the cDNA.  Therefore, we probed a neutro- 
phil-like DMSO-differentiated HL60 library  (40)  with a 5' 
fragment of the partial  cDNA  from U937.  Several longer 
clones  were sequenced.  They  all encode an open reading 
frame of 305 amino acids (Fig.  1).  As confirmation of the 
identity of the clone, several tryptic peptides obtained from 
purified protein were found in the predicted amino acid se- 
quence of IAP (dashes above the sequence in Fig. 2; top). 
The translation  initiation site shown in Fig. 1 conforms only 
poorly to the Kozak consensus (24).  It is likely that this is 
the initiation site based on the absence of a preceding initia- 
tion codon in any of the clones, the highly abnormal amino 
acid sequence that would be encoded by the CGG repeats in 
the 5' end, and the expression from the cDNA of a protein 
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Figure 2. (Top)  Amino acid sequence of human (HIAP) and murine (MIAP) IAP, as aligned with the vaccinia strain WR (37) and Variola 
(1) A38L proteins (VAWR  and VAOL, respectively). Sequences are numbered starting with the initiator methionine. The amino acid se- 
quences are given in the one-letter IUPAC code, with gaps introduced during the alignment indicated (-). Amino acids are boxed when 
the residues of three or four sequences are homologous at any given position. Apart from identities the following sets are considered to 
contain homologous amino acids: (A, I, L, M,  V), (K, R, H), (D, E), (S,  T), and (Y, F). Sequence obtained by Edman-degradation of 
tryptic IAP peptides are shown (  .... ). The first of  these was used to derive the oligonucleotides  used in cloning. Potential N-linked glycosy- 
lation sites in the IAP sequences are shown by asterisks (*) above (human) or below (murine) the sequences. For all potential glycosylation 
sites contained within sequenced peptides, the yield of the asparagine (N) was very low, as would be expected if the residue is carbohydrate- 
linked. Hydrophobic potentially membrane-spanning segments are doubly underlined ( ....  ) and numbered, starting with the predicted 
signal peptide. The predicted signal peptide cleavage site is shown by a caret (A). The carboxy-terminal sequence used for the generation 
of peptide antisera is also shown (###). The human and murine cDNA sequences are available from Genbank (accession numbers Z25521 
and Z25524). (Bottom) Alignment of the IgV-like regions from murine and human IAP with the most homologous members of the IgV 
family from Table I. The cysteine residues predicted to be disulfide linked in the IgV loop are marked by asterisks (*) below the sequences. 
Amino acids are boxed when the homology was between four or more of the sequences, according to the homology rules stated above. 
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Figure 3. FACScan profiles for staining  of CHO transfectants  with 
various anti-lAP mAbs. The panels are designated by the respective 
antibody names.  All antibodies  are marine IgG1 anti-lAP mAbs, 
except  6F2,  which is  an isotype-matched negative  control.  The 
profiles shown are from CHO cells transfected  with the human IAP- 
expressing construct plAP45 (dotted line, right hand curve) and the 
non-expressing  anti-sense  control plAP69  (solid line,  left  hand 
curve). 
identical to lAP in terms of size and antibody reactivity (see 
below).  The 3' end of the coding region of the U937 clone 
had a 3  ~o deletion (singly underlined in Fig.  1) compared 
to the I-]Lt~ :DNAs, which leads to premature termination 
of the protein  at Glu  293. This  form also constitutes  a  very 
small minority of  the clones obtained from the HL60 library. 
It presumably arose from alternative splicing of lAP mRNA, 
since both the sequence in the coding region 5' to the deletion 
and the 3' untranslated sequence of this cDNA are identical 
to those of the longer HL60 cDNAs. 
Further  evidence that the cDNAs encoded IAP was ob- 
tained by induction of anti-human IAP rnAb reactivity with 
CHO cells after transfection with IAP cDNA (Fig.  3).  This 
was  confirmed  by  immunoprecipitation  of an  appropriate 
Figure 4. (A) Immunoprecipitation of human IAP from CHO cells 
transfected with the human IAP-expressing construct plAP45 (45S) 
or the anti-sense  control pIAP69 (69A).  Human pro-myeloeytic 
U937 cells  (U937)  were used as a positive  control. Transfectants 
were grown to confluence in four 175 cm  2 flasks each,  removed 
with PBS/2 mM EDTA, surface biotinylated,  solubilized,  and im- 
munoprecipitated with anti-lAP mAb 1F7 or control mAb 6F2, as 
described in Materials  and Methods.  Under the conditions used 
(1% Triton X-100, 1% deoxycholate),  coimmunoprecipitation with 
integrins  is not seen. (B) Immunoprecipitation of lAP from human 
platelets  with rabbit antiserum directed against the predicted car- 
boxy terminus of human IAP. Platelets  were surface biotinylated 
and  solubilized.  Immunoprecipitation was first  carried out with 
a  saturating  amount  of  antibody  directed  against  the  peptide 
NQKTIQPPRNN, the predicted carboxy terminus of IAP, (CPEP) 
or preimmune serum (PI). A second round of  immunoprecipitation 
was carried out with the same rabbit serum, and this immunopre- 
cipitation revealed no antigen (second lane in each series).  The su- 
pernatant of each series  was used in immunoprecipitation again, 
this time with anti-lAP mAb 1F7. The anti-peptide  antibody recog- 
nizes  IAP and preclears all antigen  recognized by mAb 1F7. 
Mr  band  on  SDS-PAGE  from  the  transfected  CHO  with 
anti-lAP mAb (Fig. 4 A). Immunoprecipitations were done 
in 1% Triton X-100 and 1% deoxycholate, conditions under 
which integrin coimmunoprecipitation is not seen. To finally 
prove that the cDNA encoded lAP, we prepared an antibody 
Lindberg  et  al.  Cloning oflntegrin-associated Protein  489 by immunizing rabbits with a synthetic peptide made from 
the  predicted sequence of the  lAP  eDNA.  This peptide, 
NQKTIQPPRNN, was the earboxy-terminal 11 amino acids 
of the sequence of the most common form of lAP eDNA in 
the HL60 library, which encoded the longer open reading 
frame.  This anti-peptide antibody was  used  in  sequential 
immunoprecipitation with  1F7, a  previously characterized 
anti-lAP mAb (5). Under the conditions of cell lysis and im- 
munoprecipitation, lAP migrates as a 50-kD protein on Su- 
perose 12 chromatography (data not shown), which is the 
size of the monomeric protein on SDS-PAGE. As shown in 
Fig. 4 B, antibody against the predicted sequence completely 
precleared all  1F7-immunoprecipitable lAP  antigen  from 
human platelets. Thus, the lAP cDNA encodes tryptic pep- 
tides of placental IAE confers reactivity with all anti-lAP 
mAb on CHO cells, and antibody made against a peptide se- 
quence predicted by the eDNA is able to recognize native 
lAP in platelets. Thus, the eDNA encodes IAE 
Murine IAP was cloned from a 70Z/3 pre-B cell eDNA 
library by homology to human lAP. Its predicted amino acid 
sequence is 71%  identical and 87%  similar to human lAP 
(Fig. 2). There is a 2-amino acid deletion and a 21-amino 
acid insertion in murine IAP relative to the human protein. 
The predicted carboxy terminus of murine lAP shows iden- 
tity at 9 of 11 amino acids, and the polyelonal anti-peptide 
antibody made against the predicted human sequence immu- 
noprecipitated a 48-kD protein from surface-labeled murine 
platelets,  erythrocytes, and splenocytes (data not shown). 
Thus, the murine eDNA, like the human, encodes a widely 
expressed plasma membrane protein. 
lAP Is Homologous to Poxvirus Proteins and Contains 
an Immunoglobulin Domain 
When the lAP protein sequence was compared to Genbank 
sequences, human IAP was  found to be identical to a  re- 
cently cloned ovarian carcinoma antigen recognized by the 
mAb OVTL3 (7). The sole difference found was the absence 
in the OVTL-3 5' untranslated sequence of the guanidine at 
position -85 of the human IAP cDNA sequence (Fig. 1). IAP 
is highly homologous to open reading frame A38L of the 
Vaeeinia (alignment scores of 8.6 and 7.8 with human and 
murine IAP, respectively) and Variola major virus genomes 
(Fig. 2; top) (1,  12). 
Kyte-Doolittle (39) hydrophobicity analysis (Fig. 5) indi- 
cates that lAP and A38L can be divided into a hydrophilie 
amino-terminal half and a hydrophobie earboxy-terminal do- 
main.  There  is  also  an  amino-terminal  hydrophobie  se- 
quence which has the features of a signal peptide. Whether 
the amino terminus of lAP forms a transmembrane domain 
or is a signal sequence is currently unknown since the amino 
terminus of lAP purified from placenta, erythrocytes, and 
HL60, is blocked. The highly homologous A38L proteins 
have too few amino acids at their amino termini to form a 
membrane-spanning domain but these amino termini likely 
encode signal peptides. By analogy, the 20 amino acids at the 
amino terminus of lAP are likely to form a signal peptide. 
The blocked amino terminus of mature lAP may well begin 
with a pyrollidone earboxylie acid at Q19. 
The hydrophilie sequence after the putative signal peptide 
has three cysteines. The regions around the second and third 
of these show homology to the corresponding regions of sev- 
eral proteins in members the immunoglobulin superfamily. 
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Figure 5.  Assignment of membrane-spanning  regions  of lAP. 
Shown are hydrophobicity profiles (see Materials and Methods) for 
human and murine IAP, aligned by the carboxy-termini of the pro- 
teins. The horizontal axes are amino acid position in the respective 
protein and the vertical axes are arbitrary hydrophobicity units. The 
predicted membrane-spanning segments are indicated by horizon- 
tal  bars  numbered  2  through  6.  The presumed  signal peptide 
(membrane-spanning segment  1) is  not  shown. The lower half 
shows the vaccinia A38L hydrophobicity plot aligned with IAP by 
the membrane-spanning regions. 
Further comparison shows that the amino terminus of IAP 
is most related to the IgV family, with significant homology 
to multiple family members (Table I; Fig. 2; bottom). 
Anti-IAP mAbs Recognize the IgV-like Domain 
Previous work has functionally characterized multiple anti- 
IAP mAb and demonstrated at least three distinct antigenic 
extracellular epitopes by crossinhibition and immunofluo- 
rescence studies (5). Therefore, we investigated which IAP 
domains are recognized by these various mAbs.  Chimeric 
cDNAs  were constructed which  encoded hybrid proteins 
with the human immunoglobulin-like loop and murine trans- 
membrane domain and the inverse construct encoding a mu- 
rine immunoglobulin-like loop with human transmembrane 
domains.  These chimeric constructs were transcribed and 
translated in vitro, and the translated products immunopre- 
cipitated with anti-human lAP mAbs. As shown in Fig. 6, 
all seven anti-human mAb recognized proteins containing 
the human IgV-like domain, regardless of whether the rest of 
the molecule was murine or human sequence. The data were 
confirmed by FACS analysis of stable CHO transfeetants ex- 
pressing  the  same  chimeric  eDNA  constructs  (data  not 
shown). These results demonstrate that this large hydrophilic 
domain is indeed extracellular. 
lAP Membrane-spanning Segments 
The carboxy-terminal hydrophobie regions of both IAP and 
the A38L proteins have five potential membrane-spanning 
segments (Fig. 5 and Fig. 2, top). Flanking segment 2 are 
basic residues to provide phospholipid anchoring (human 
The Journal of Cell Biology,  Volume 123, 1993  490 Table L Alignment Scores  for the Comparison of  Human and Murine lAP to Vaccinia A38L and to Members of 
the Ig  V Immunoglobulin Superfamily 
Sequence  HIAP  MlAP  VACC  CLNK  PIGR  HEAV  LAMB  CD4  CD8  OX-2  MYP0 
Human IAP  HIAP 
Murine IAP  MIAP  15.0 
Vaceinia A38L  VACC  7.2  7.0 
Human cartilage link protein  CLNK  4.2  6.1  5.3 
Rabbit poly Ig receptor  PIGR  2.5  2.3  2.7  2.2 
Human Ig heavy chain  HEAV  2.8  3.4  2.5  2.7  2.4 
Mouse Ig lambda chain  LAMB  3.0  3.7  1.1  2.9  2.4 
Human CD4  CD4  4.3  3.5  5.1  3.6  5.3 
Rat CD8 beta  CD8  2.9  2.5  4.0  2.0  2.9 
Rat Ox-2  OX-2  2.5  2.7  1.8  1.9  2.2 
Rat myelin P0  MYP0  4.4  3.2  2.7  5.7  3.6 
Rat Thy-1  THY1  3.2  2.6  2.8  2.5  2.4 
4.8 
2.2  4.1 
4.8  4.8  3.9 
0.8  2.3  1.4  2.4 
2.8  0.3  4.6  2.3 
1.1  3.4  3.8  3.0 
2.4 
4.9  2.4 
Sequences were aligned using the Needleman and Wunsch algorithm (10) using the PAM250 protein alignment matrix, with a bias of 10 and a gap penalty of 
10. The score obtained for each pair was compared to that obtained aligning 150 random permutations of the sequences. The real score is expressed as standard 
deviations above the mean of the random scores. Sequences  were obtained from the Swiss Protein Database. The comparison was performed using sequences from 
7 amino acids before the first eysteine through position 8 after the second cysteine forming the known or predicted disulfide bond. The sequences are Human 
lAP (residues 33-122), murine lAP (33-120), Vaccinia A38L (29-107) accession number P24768 (12), human cartilage link protein (54-167) X17405 (19). The 
other sequences were used in Williams and Barclay (36) to define the IgV family and are referenced there. The accession numbers and residues included in the 
comparison are Rabbit polymeric Ig receptor precursor second IgV-iike domain P01832 and 148-233, human Ig heavy chain variable region P01825 and 15-103, 
mouse Ig lambda chain variable region P01724 and 34-117, human CD4 IgV-like domain P01730 and 34-117, rat CD8 beta chain IgV-like domain P05541 and 
34-123,  rat ox-2 glycoprotein P04218 and 44-129,  rat myelin P0 protein P06907 and 43-135,  rat Thy-I antigen P01830 and 21-122. 
Kt63/K  165,  mouse  Kt6t/KtS4).  Similarly,  there  are  K 175  and 
R ~  at  the  amino-terminal  border  of  segment  3,  and  K 29° 
and K 31° at the carboxy-ternainal border of segment 6.  Seg- 
ment 5 is similarly delimited in the A38L proteins, with very 
high  homology  to  IAP  in  this  region,  as  is  the  carboxy- 
terminal  end of segment 4.  The presence  of strongly helix 
breaking H TM in human  segment 4  (Fig. 2; top) and the rel- 
ative hydrophobicity  of the region between segments 4  and 
5,  make the assignment  of segment 4  more tentative.  This 
segment  alone  or  together  with  segment  5  could  be  a 
membrane-associated  rather  than  membrane-spanning 
region. 
Immunolocalization of the lAP Carboxy Terminus 
Since the total number of membrane-spanning  segments af- 
ter  the  IgV  domain  would  affect  the  localization  of  the 
carboxy-terminal hydrophilic peptide,  we decided to deter- 
mine whether the carboxy terminus is located on the inside 
Figure 6. In vitro translation of human-mouse 
chimeric LAPs  and irnmunoprecipitation with 
different  LAP  mAbs.  The  IAPs  were  human 
(Human),  murine  (Mouse), murine  with  hu- 
man hydrophilic domain (HumEC), or human 
with  marine  hydrophilic  domain  (MusEC). 
The  recombination point between the  hydro- 
philic  domain  and  the  carboxy-terminal  re- 
mainder of the molecule was at W 13s (human 
numbering,  see  Fig.  1).  The  [35S]methionine 
labeled in vitro synthesized LAPs were immu- 
noprecipitated with the various LAP antibodies 
(B6H12, 1FZ 2B7, 2D3, 2Ell, 3E9, or 3G3) or 
negative  isotype-matched  control  antibody 
(6F2). 
Lindberg et al. Cloning  of lntegrin-associated Protein  491 Figure 7. Immunolocalization of the human IAP carboxy terminus 
in human T24 cells. Cells adherent to glass slides were stained with 
murine  anti-human IAP mAb 2D3 (2D3) reacting with the ex- 
tracellular  aspect of lAP, with miapl31  (131) or miapl51 (151) 
reacting with the carboxy terminus, or with the irrelevant control 
mAb 6F2 (6F2). The left hand column shows fluorescence micro- 
graphs of cells stained before methanol treatment (non-fixed). The 
right  hand micrographs  are  of cells  stained  after permeabiliza- 
tion/fixation with  methanol  (fixed). The  anti-carboxy  terminus 
mAbs stain only permeabilized cells suggesting that the epitope is 
located intracellularly. Isolated membranes  from I24 cells also 
showed specific staining with these mAbs (data not shown). 
or  outside  of  the  cytoplasmic  membrane.  Human  T24 
uroepithelial carcinoma cells were stained with or without 
prior  permeabilization  with  methanol  with  mouse  mAbs 
miapl31 and miapl51 against the human lAP carboxy termi- 
nus (see Materials and Methods). As controls, 2D3 binding 
to extracellular parts of IAP and negative antibody 6F2 were 
used. As shown in Fig. 7, both miapl31 and miapl51  stain 
T24 cells only after methanol permeabilization, suggesting 
that the carboxy terminus is located in the cytoplasm. This 
in turn implies that the carboxy-terminal hydrophobic do- 
main  of IAP must  encode an  odd  number of membrane- 
spanning segments. 
Structural Model  for lAP 
From this information a structural model of lAP was made 
(Fig.  8).  This model predicts a protein with an amino-ter- 
minal IgV-like extracellular domain and a carboxy-terminal 
multiply membrane-spanning domain. The IgV-like domain 
contains all but one predicted N-glycosylation sites. At least 
four of these sites are used, since amino acid sequencing of 
tryptic peptides from IAP purified from placenta gave very 
low yields at the predicted Asn. The IgV homology suggests 
the disulfide linkage shown in Fig. 8, although its presence 
has not been shown experimentally. Since the IgV-like do- 
main is extracellular and the carboxy terminus intracellular, 
the carboxy-terminal hydrophobic domain has an odd num- 
ber of  membrane-spanning segments. The hydropathy plot of 
this region is consistent with 5 transmembrane domains as 
shown. However, the assignment of segment 4  (third trans- 
membrane segment in Fig.  8) is more tentative due to the 
lack of a basic phospholipid anchoring amino acid and the 
presence of a histidine near the center of the segment. If seg- 
ment 4 is not membrane spanning, this would have to be true 
also of segment 3 or 5. The strongly hydrophobic character 
of these regions of  lAP suggest that they would be membrane- 
associated if not membrane-spanning. 
Anti-lAP Inhibits a,/3r~lependent  Ligand Binding 
IAP  is  a  widely expressed protein,  present on many cell 
types and was initially copurified with OLv133 from placenta. 
Anti-IAP antibodies inhibit binding of  multivalent RGD- and 
KGAGDV-peptides to polymorphonuclear cells (PMN) (16, 
17),  but careful study of the functional effect of these anti- 
bodies has been limited to this genetically nonmanipulatable 
system. To determine whether anti-lAP mAb might affect 
O~v133 function,  we  examined the  binding  of Vn-  and  Fn- 
coated beads  to  HEL cells,  which  are  known to  express 
OevJ33 and  ~sfl~. Anti-IAP  mAb  B6H12,  which  inhibits 
ligand bead binding to PMN (16),  inhibited the binding of 
Vn-beads but not Fn-beads to these cells (Fig. 9). Anti-IAP 
mAb 2D3,  which does not inhibit ligand-bead binding to 
PMN,  also did not inhibit Vn-bead binding to HEL cells. 
Binding of Vn-beads was inhibited both by polyclonal anti- 
c~v/33 and by the anti-/33 mAb 7G2. These data demonstrate 
that anti-lAP mAb can inhibit Vn binding to o~vfl3, but does 
not affect Fn binding to ot5/3~ on the same cells. 
Anti-Human lAP mAb Inhibit Vitronectin Receptor 
Function in Transfected CHO Cells 
We used the ability of anti-lAP to inhibit Vn binding to av 
integrin receptors to examine the function of transfected hu- 
man IAP in CHO cells, using mAbs that recognized only the 
transfected human molecule. In these cells transfected with 
IAP eDNA, half or less of the total expressed LAP was hu- 
man, as judged by alteration in binding of polyclonal anti- 
IAP  (Fig.  10 A).  Polyclonal anti-human  lAP  recognized 
hamster IAP (Fig.  10 A) and inhibited binding of Vn-beads 
to untransfected CHO cells and CHO cells transfected with 
the control reverse eDNA  (Fig.  10 B).  In  contrast,  anti- 
human lAP mAb neither recognized these CHO cells nor 
affected Vn-beads binding. In CHO cells expressing human 
IAP, as in HEL cells, B6H12 inhibited Vn-beads binding as 
completely as polyclonal anti-lAP (see Discussion). Again, 
as for HEL cells, 2D3 did not affect Vn-bead binding (Fig. 
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human  IAP. The  model  is 
based on predictions from the 
primary sequence, as derived 
from the cDNA sequence, as 
well  as  homology  to  known 
members of the immunoglob- 
ulin  superfamily.  The poten- 
tial  N-linked  glycosylation 
sites are shown, and are pre- 
sumed  to  be  extracellular. 
Low yields of the correspond- 
ing asparagines by amino acid 
sequencing  suggests  that  at 
least  the  second  through 
fourth potential  glycosylation 
sites carry carbohydrate. The 
hydrophilic region has consid- 
erable similarity to immuno- 
globulin variable regions. The 
disulfide linkage suggested by 
this  homology  is  indicated, 
but  its  presence  or  absence 
has  not  been experimentally 
investigated. The carboxy ter- 
minus is located on the inside 
of  the  cell  membrane.  The 
assignment  of  membrane- 
spanning segments is tentative 
and it is possible that the third 
segment is membrane-associ- 
ated  rather  than  membrane- 
spanning.  In  this  case,  this 
would have to be true for at 
least  one  other  hydrophobic 
segment,  since  an odd  num- 
ber of transmembrane regions 
would be required to connect 
the  extracellular  IgV domain 
to  the  intracellular  carboxy 
terminus. 
10 B). Fn-beads binding to CHO cells was not inhibited by 
monoclonal or polyclonal anti-lAP antibodies in the trans- 
fectants or the  control cells (data not shown).  These data 
suggest  that  human  lAP  can  associate  with  hamster  o~v 
receptor(s). 
Discussion 
We have previously described a 50-kD protein which copuri- 
fled with olv~3 from placenta and which coimmunoprecipi- 
tared with/~3  integrins  from platelets.  Because of this,  we 
called  this  protein  the  Integrin  Associated  Protein,  IAP. 
Now, we have cloned IAP cDNA. The proof that the cloned 
molecule is IAP is that (a) several tryptic peptides derived 
from native placental IAP are found in the predicted amino 
acid sequence of the clone; (b) the product of in vitro tran- 
scription/translation of the cloned cDNA is recognized by all 
anti-IAP mAb;  (c)  transfection  of the  human cDNA  into 
CHO cells confers reactivity with mAb specific for human 
IAP on the transfectants; and (d) immunoprecipitation with 
a  cDNA  sequence  derived carboxy-terminal peptide  anti- 
body preclears all lAP reactivity from a platelet lysate. The 
predicted amino acid sequence of the cDNA is highly hydro- 
phobic and predicts a  molecule with a  single extraceUular 
IgV-like domain and multiple membrane-spanning segments. 
Because immunoglobulin domains are often involved in in- 
termolecular interactions, this structure suggests the hypoth- 
esis that the extracellular domain is important in the interac- 
tion of lAP with its associated integrins. The relative lack of 
conservation of the extracellular domain between mouse and 
human lAP (61%  compared to 77%  in the multiple trans- 
membrane domains) is still consistent with this hypothesis, 
since the amino acid sequence of ICAM-1, another immuno- 
globulin  superfamily molecule which  interacts  with  inte- 
grins,  is even less conserved between these species (20). 
The sequence of IAP is identical to the sequence of a re- 
cently cloned ovarian carcinoma antigen  (7).  This antigen 
was  cloned  because  it  was  recognized  by  an  "ovarian 
carcinoma-specific" antibody, OVTL3 (3, 29). We cannot ex- 
plain why lAP, which is ubiquitously expressed, was thought 
to be a  carcinoma-specific antigen.  Campbell et al.  report 
that mRNA for this protein is present in all normal tissues 
tested  (7).  In our hands  (data not  shown),  as  well as  for 
Campbell  et  al.  (7),  OVTL3  recognizes  IAP  on  several 
Lindberg et al.  Cloning of lntegrin-associated Protein  493 Figure 9. (A) Binding of Vn-beads to HEL cells. The ability  of HEL 
cells to recognize and attach ligand-coated beads was assessed as 
described in Materials and Methods. Attachment was quantitated 
as attachment index (AI), the number of beads bound/100 cells. 
Control represents binding in the presence of non-immune rabbit 
IgG, which is not different from buffer alone. Anti-IAP (5), anti- 
LRI (8), and anti-VnR are IgG fractions of rabbit antisera. 2D3 and 
B6H12  are IgG1  anti-IAP mAb, and 7(32 is IgG1  anti-/~3 mAb. 
The experiment shown is representative of at least six repetitions 
for each  antibody.  Controls  included KGAGDV-beads  (a ligand 
specific for LRI [17]) and HSA beads. These experiments demon- 
strate that both C~vB3 and lAP were required for Vn-beads binding 
by HEL cells. (B) Binding of Fn-beads to HEL cells. These experi- 
ments were performed as in A, except that the ligand coating on the 
bead was Fn and the incubation buffer differed in divalent cation 
content (see Materials and Methods). The binding of Fn-beads to 
HEL was dependent on t~5/3t but was independent of IAP. 
Figure 10,  (A) Fluorescence flow cytometry of CHO cells trans- 
fected with human lAP cDNA. CHO cells were transfected with 
constructs of either full length human lAP eDNA (plAP45) (solid 
line, dashed line [---]) or of anti sense eDNA (plAP69) as a control 
(small and large dotted lines  [o,  o]), as in Figs. 3 and 4 A.  The 
CHO cells were analyzed by fluorescence flow cytometry using 
polyelonal  anti-lAP (5) (e, ---) or preimmune serum (., solid line). 
Both the human lAP transfectant and the control are recognized by 
the polyelonal anti-lAP. The human lAP transfectant has a mean 
fluorescence with anti-lAP about twice that of the control.  (B) 
Binding of Vn-beads to CHO transfectants. CHO cells, transfected 
with either human lAP eDNA (45S) or anti-sense (69A), as in A, 
were tested for their binding of  Vn-beads in the presence of the same 
antibodies tested in Fig. 9. Data are the mean +  SD for three inde- 
pendent experiments done in duplicate. Attachment was quantitated 
as AI (see Materials and Methods). B6HI2, which recognizes only 
human IAP, completely inhibits Vn-beads binding to 45S  cells, 
even though it does not recognize hamster lAP. 
different cells, including CHO cells transfeeted with human 
IAP cDNA. Perhaps the specificity has a quantitative rather 
than  qualitative basis.  IAP also is homologous to  the ex- 
pected product of the poxvirus A38L reading frame (1,  12, 
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terminal  unpaired  cysteine,  which  could  form  disulfide 
bonds with other molecules.  However, we have not seen 
covalent interaction of IAP with itself or with any other pro- 
teins. The high degree of  conservation of the LAP homologue 
between Vaccinia and Variola suggests that this protein has 
an important role in the viral life cycle. Many viral proteins 
have been shown to influence pathogenesis by mimicking or 
inhibiting host molecules (13). The function of  this viral pro- 
tein remains unknown. 
The multiple membrane-spanning domains in the carboxy 
terminus of IAP suggest several testable possible roles for 
lAP in signal transduction. One possibility is that this region 
of IAP has a transporter or channel function. In this regard, 
adhesion of endothelial cells to vitronectin or fibronectin 
causes an increase in [Ca+2]i (34), which can be blocked by 
B6H12, but not 2D3,  suggesting that IAP is involved in the 
signaling for Ca  ÷2 entry into the ceils (34a).  However,  as 
yet, we have no direct experimental data to support the hy- 
pothesis that LAP can itself act as a membrane channel. 
IAP was defined originally as the target of a monoclonal 
antibody, B6H12, which inhibited the function of a leukocyte 
B3-1ike integrin, the LRI. Functional inhibition by B6H12 
involved its ability to block ligand binding to LRI (16, 17). 
In the current study, we have shown that anti-LAP also can 
block ligand binding to the much better characterized Vn 
receptor, txv~3, on HEL cells and to Otv receptors on CHO 
cells. Moreover, binding of  Vn-coated particles to CHO cells 
transfected with human LAP was completely inhibited by 
B6H12, which recognizes human but not hamster LAP. This 
dominant effect of the anti-human IAP mAb is very surpris- 
ing in view of the presence of non-inhibited hamster LAP on 
these cells.  This would be expected if B6H12-bound IAP 
binds to the integrin in an inhibitory fashion. B6H12 may 
stabilize a conformation of human LAP which favors physical 
and functional association with CHO ctvB3. We have previ- 
ously shown that lAP is capable of existing in two conforma- 
tional states with different affinities for B6H12 (30). Another 
possibility is that the antibody to lAP might generate a signal 
inhibitory to otvB3 and LRI ligand binding, independent of 
its ability to associate with these integrins. This would have 
to be a very specific negative signal, since binding of Fn- 
coated  beads  to  another  integrin  on  the  same  ceils  is 
unaffected  by B6H12. In addition, kinetic studies of Vn-bead 
binding to HEL cells indicate that the initial rate of Vn bind- 
ing is unaffected by B6H12 (Gresham, H. D., unpublished 
observation). If the antibody were simply activating a nega- 
tive signal, even one specific for o~B3, this would not be ex- 
pected.  Furthermore, data obtained with PMN  show that 
B6H12 but not 2D3 can stimulate the respiratory burst when 
adherent to a tissue culture plate and that this respiratory 
burst is inhibited by anti-LRI mAb and LRI ligands in solu- 
tion (41). These data favor the possibility that B6H12  can 
stabilize a signal transduction complex which contains both 
LRI and LAP, suggesting a model in which LAP association 
with  integrins  is  dynamic,  possibly  affected by  integrin 
ligands or other environmental influences on cell phenotype 
and by some anti-LAP  mAbs.  Notably, cytokine receptor 
complexes often contain a transmembrane protein which is 
not directly involved in ligand binding but which is critical 
for high affinity ligand binding and signal transduction (11, 
23, 26, 28). Gpl30 functions in this way as a component of 
the IL6 and LIF receptors, as does the/3 chain of the IL3, 
IL5, and GM-CSF receptors (14, 18 23, 28, 38).  In at least 
one case, that of gp130, ligand is required to stabilize the as- 
sociation of this additional chain with the ligand binding 
subunit of  the IL6 receptor (18, 38). At this time, the associa- 
tion of gpl30 with the IL6 receptor appears to be a reason- 
able model for the association of IAP with LRI and t'¢,/~3. 
The existence of at least one other immunoglobulin super- 
family member which modulates integrin binding of ligands 
(21) suggests that LAP-like molecules may be a general mech- 
anism involved in integrin dependent signal transduction. 
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